HC Wainwright Reaffirms “Buy” Rating for Dianthus Therapeutics (NASDAQ:DNTH)
HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report issued on Monday, Benzinga reports. They currently have a $40.00 target price on the stock. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q3 2024 earnings at ($0.53) EPS, Q4 2024 earnings at ($0.73) EPS, FY2024 earnings […]
More Stories
Shots Fired at White House Correspondents’ Dinner, Trump Evacuated, Suspect Detained
By Emel Akan and Sam Dorman President Donald Trump and First Lady Melania Trump were evacuated from the White House...
US Forces Intercept, Turn Back Iran-Linked Tanker in Arabian Sea
By Ryan Morgan A U.S. Navy helicopter intercepted and turned back toward Iran a sanctioned petrochemical tanker in the Arabian...
Iran Offered Better Deal ‘10 Minutes’ After US Canceled Pakistan Meeting, Trump Says
By Jacki Thrapp The Iranian regime offered the United States a “much better” peace deal within 10 minutes of President...
Iran Delegation Leaves Pakistan Without US Talks as Trump Cancels Envoy Visit
By Tom Ozimek Iranian Foreign Minister Abbas Araghchi left Pakistan for Oman on Saturday without meeting U.S. negotiators. Araghchi met...
SBA Refers 562,000 Suspected Fraudulent Loans Worth $22.2 Billion to Treasury
By Naveen Athrappully The Small Business Administration (SBA) has referred 562,000 loans suspected to be fraudulent to the Treasury Department...
US Exports of Crude and Petroleum Products Hit Record Highs
By Jacki Thrapp America’s energy exports have hit record highs as the world navigates the uncertainty surrounding oil and gas...